The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing.

  • Yogev-Falach M
  • Amit T
  • Bar-Am O
 et al. 
  • 20


    Mendeley users who have this article in their library.
  • 98


    Citations of this article.


Rasagiline [N-propargyl-(1R)-aminoindan] a highly potent selective irreversible monoamine oxidase (MAO)-B inhibitor exerts neuroprotective and antiapoptotic effects against a variety of insults in cell cultures and in vivo and has finished its phase III clinical trials for Parkinson's disease. In the present study, we show that rasagiline (1 and 10 microM) significantly protected rat PC12 cells against beta-amyloid (Abeta1-42) toxicity. In addition, rasagiline significantly increased (approximately threefold) the secretion of the nonamyloidogenic soluble form of the amyloid precursor protein (sAPPalpha) from SH-SY5Y neuroblastoma and PC12 cells. The increase of sAPPalpha was dose-dependent and was blocked by the hydroxamic acid-based metalloprotease inhibitor Ro31-9790 (100 microM), suggesting that the effect is mediated via alpha-secretase activity. Rasagiline-induced sAPPalpha release was significantly reduced by the inhibitors of protein kinase C (PKC), GF109203X, and ERK mitogen-activated protein kinase (MAPK) PD98059. Moreover, rasagiline dose dependently (0.1-10 microM) increased the phosphorylation of p44 and p42 MAPK, which was abolished by PD98059 (30 microM) and GF109203X (2.5 microM). By comparing the actions of rasagiline with those of its S-isomer TVP1022, which is not an MAO inhibitor, we have been able to demonstrate that MAO-B inhibition is not a prerequisite for either sAPPalpha-induced release or ERK phosphorylation. In addition, structure-activity relationship among rasagiline-related compounds suggests the crucial role of the propargyl moiety in these molecules, because propargylamine itself significantly induced the secretion of sAPPalpha and increased MAPK phosphorylation with similar potency to that of rasagiline and its derivatives.

Author-supplied keywords

  • Amyloid beta-Peptides
  • Amyloid beta-Peptides: toxicity
  • Amyloid beta-Protein Precursor
  • Amyloid beta-Protein Precursor: metabolism
  • Animals
  • Antiparkinson Agents
  • Antiparkinson Agents: chemistry
  • Antiparkinson Agents: pharmacology
  • Cell Line, Tumor
  • Indans
  • Indans: chemistry
  • Indans: pharmacology
  • MAP Kinase Signaling System
  • Mitogen-Activated Protein Kinases
  • Mitogen-Activated Protein Kinases: metabolism
  • Models, Biological
  • Neuroprotective Agents
  • Neuroprotective Agents: chemistry
  • Neuroprotective Agents: pharmacology
  • PC12 Cells
  • Pargyline
  • Pargyline: analogs & derivatives
  • Pargyline: pharmacology
  • Peptide Fragments
  • Peptide Fragments: metabolism
  • Peptide Fragments: toxicity
  • Propylamines
  • Propylamines: pharmacology
  • Protein Processing, Post-Translational
  • Rats
  • Structure-Activity Relationship

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Merav Yogev-Falach

  • Tamar Amit

  • Orit Bar-Am

  • Moussa B H Youdim

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free